SGLT2 抑制剂联合GLP-1 受体激动剂治疗2 型糖尿病合并心血管疾病的研究进展
| 作者: |
1赵喆,
1杨丹丹,
1詹晓蓉
1 哈尔滨医科大学附属第一医院内分泌三科，哈尔滨 150001 |
| 通讯: |
詹晓蓉
Email: xiaorongzhan@sina.com |
| DOI: | 10.3978/j.issn.2095-6959.2019.06.031 |
摘要
目前糖尿病患病率越来越高，且相当大一部分合并心血管疾病，SGLT2抑制药及GLP-1受体激动药可从降糖、减重、降压、保护肾功等多个角度间接及直接地减少糖尿病患者的心血管不良事件和心血管病病死率。
关键词：
2型糖尿病；心血管事件；钠葡萄糖协同转运蛋白2抑制剂；胰高血糖素样肽-1受体激动剂
Research advance in SGLT2 inhibitor combined with GLP-1 receptor agonist in the treatment of type 2 diabetes with cardiovascular disease
CorrespondingAuthor: ZHAN Xiaorong Email: xiaorongzhan@sina.com
DOI: 10.3978/j.issn.2095-6959.2019.06.031
Abstract
At present, the prevalence of diabetes mellitus is getting higher and higher, and a considerable part of them have cardiovascular disease. SGLT2 inhibitors and GLP-1 receptor agonists can reduce cardiovascular adverse events and cardiovascular mortality in diabetic patients from the angles of reducing blood sugar, weight, blood pressure and kidney function.
Keywords：
type 2 diabetes mellitus; cardiovascular events; sodium glucose cotransporter 2 inhibitors; glucagon like peptide 1 receptor agonists